ArticleArchives of endocrinology and metabolism2026
LncRNA GSEC impedes the reprogramming of glucose metabolism in papillary thyroid carcinoma by inhibiting the IGF2BP2/GLUT1 axis.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression pattern of lncRNA GSEC in papillary thyroid carcinoma (PTC) and elucidate its functional role and molecular mechanism in regulating glycolytic metabolism and malignant progression. MATERIALS AND
methodsThe expression levels of the GSEC gene in thyroid cancer were determined through bioinformatics analysis of the TCGA database, and potential downstream regulatory genes were predicted. GSEC mRNA levels in normal thyroid cells and thyroid cancer cells were detected by qRT-PCR. Cellular functions, including proliferation, invasion, and migration, were evaluated using CCK-8 assays, Annexin-V/PI staining, western blot, EdU staining, Transwell assays, and scratch tests. Glycolytic activity was assessed by western blot, glucose uptake assays, and measurements of extracellular lactate levels. Subcutaneous and metastatic papillary thyroid carcinoma (PTC) models were established in nude mice to investigate the effects of lncRNA GSEC expression on tumor growth and metastasis.
resultsLncRNA GSEC expression was significantly downregulated in thyroid cancer. Overexpression of GSEC in PTC-1 cells effectively inhibited their proliferation, invasion, and migration. GSEC downregulated GLUT1 expression by inhibiting IGF2BP2, thereby disrupting glycolysis and suppressing tumor growth and invasion. In vivo assay demonstrated that GSEC overexpression significantly reduced tumor glycolysis, retarded tumor growth, and inhibited metastasis.
conclusionLncRNA GSEC is a key factor in the progression of PTC. By modulating the IGF2BP2/GLUT1 axis, GSEC affects cancer cell glycolysis, presenting a new potential target for metabolic intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.